ATYR insider transaction filings
aTYR PHARMA INC — 30 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-28. Screen ATYR transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for ATYR between 2026-06-25 and 2026-09-23. The table below lists the most recent filings on record.
Recent Form 4 filings — aTYR PHARMA INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-28 | 4 | SCHIMMEL PAUL — Director | Purchase (P): 100,000 @ $0.50 | EDGAR |
| 2026-05-13 | 4 | Lucas Svetlana — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Gross Jane A — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | BENEVICH ERIC — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Zaknoen Sara — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Coughlin Timothy — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | SCHIMMEL PAUL — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Shukla Sanjay — President and CEO, Director | Option exercise (M): 10,375 · Sale (S): 3,745 @ $0.98 · Option exercise (M): 10,375 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | DENYES NANCY — General Counsel | Option exercise (M): 2,687 · Sale (S): 1,118 @ $0.98 · Option exercise (M): 2,687 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Broadfoot Jill Marie — Chief Financial Officer | Option exercise (M): 3,750 · Sale (S): 1,558 @ $0.98 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Shukla Sanjay — President and CEO, Director | Grant/award (A): 1,500,000 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | DENYES NANCY — General Counsel | Grant/award (A): 412,500 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Broadfoot Jill Marie — Chief Financial Officer | Grant/award (A): 412,500 (derivative) @ $0 | EDGAR |
| 2025-10-09 | 4 | SCHIMMEL PAUL — Director | Purchase (P): 682,001 @ $0.90 · Purchase (P): 317,999 @ $0.94 | EDGAR |
| 2025-05-02 | 4 | Zaknoen Sara — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | Lucas Svetlana — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | Gross Jane A — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | BENEVICH ERIC — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | COUGHLIN TIMOTHY — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | SCHIMMEL PAUL — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | Gross Jane A — Director | Purchase (P): 3,750 @ $4 | EDGAR |
| 2025-02-04 | 4 | Shukla Sanjay — President and CEO, Director | Option exercise (M): 10,375 · Option exercise (M): 10,375 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | DENYES NANCY — General Counsel | Option exercise (M): 2,687 · Sale (S): 899 @ $3.78 · Option exercise (M): 2,687 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Broadfoot Jill Marie — Chief Financial Officer | Option exercise (M): 3,750 · Sale (S): 1,254 @ $3.78 · Option exercise (M): 3,750 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | Shukla Sanjay — President and CEO, Director | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | Broadfoot Jill Marie — Chief Financial Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | DENYES NANCY — General Counsel | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | BENEVICH ERIC — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-07-24 | 4 | SCHIMMEL PAUL — Director | Purchase (P): 41,052 @ $1.74 · Purchase (P): 6,648 @ $1.82 · Purchase (P): 52,300 @ $1.93 | EDGAR |
| 2024-06-06 | 4 | DENYES NANCY — General Counsel | Purchase (P): 5,000 @ $1.86 | EDGAR |
Recent 8-K events — aTYR PHARMA INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-06-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-05 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ATYR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →